Results 21 to 30 of about 21,074 (263)
Analytic framework for peptidomics applied to large-scale neuropeptide identification
Nature Communications, 2016 Neuropeptide research is challenged by technical difficulties in identifying new bioactive peptides. Here the authors present an analytical pipeline for large-scale peptidomics applied to the rat hypothalamus, identifying thousands of endogenous ...
Anna Secher +6 more
doaj +1 more source
The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism
Frontiers in Endocrinology, 2022 Incretin hormones play an important role in the regulation of glucose homeostasis through their actions on the beta cells and other tissues. Glucagon-like peptide-1 (GLP-1) and glucose dependent insulinotropic polypeptide (GIP) are the two main incretins
Melinda Danowitz +2 more
doaj +1 more source
Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
Biology, 2020 Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are secreted from the gut upon nutrient stimulation and regulate postprandial metabolism.
Geke Aline Boer, Jens Juul Holst
doaj +1 more source
Vitae, 2022 Background: Diabetes mellitus treatment is based on oral hypoglycemic agents or insulin. Medicinal plants constitute an option, and the leaves of Prosopis ruscifolia (Pr) were shown to be effective in reducing glycemia in hyperglycemic animals. Objective:
María Luisa Kennedy +4 more
doaj +1 more source
Indian Journal of Endocrinology and Metabolism, 2012 Nutrient excess results in systemic inflammation in diabetes contributing to insulin resistance, dyslipidaemia and increased cardiovascular risk. GLP-1 agonists and DPP-4 inhibitors, which are now well accepted therapies for diabetes may play a unique role in modulating this inflammatory process.
openaire +3 more sources
Update on incretin hormones [PDF]
Annals of the New York Academy of Sciences, 2011 The incretin hormones glucagon‐like‐peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) are released from the intestine following oral ingestion of nutrients. Incretins promote insulin secretion, while GLP‐1 also inhibits glucagon release and gastric emptying, minimizing postprandial glucose excursions.
Phillips, Liza K., Prins, Johannes B.
openaire +5 more sources
Why Are Incretin-Based Therapies More Efficient in East Asians? Perspectives from the Pathophysiology of Type 2 Diabetes and East Asian Dietary Habits [PDF]
European Medical Journal Diabetes, 2015 Type 2 diabetes mellitus (T2D) is one of the most serious global health problems. This is partly a result of its drastic increase in East Asia, which now comprises more than a quarter of the global diabetes population. Ethnicity and lifestyle factors are
Daisuke Yabe +3 more
doaj
Arthritis &Rheumatology, EarlyView.Objective Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.
Joseph F. Merola +14 more
wiley +1 more source
Variation in responses to incretin therapy: Modifiable and non-modifiable factors
Frontiers in Molecular Biosciences, 2023 Type 2 diabetes (T2D) and obesity have reached epidemic proportions. Incretin therapy is the second line of treatment for T2D, improving both blood glucose regulation and weight loss.
Gregory O. Austin, Alejandra Tomas
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić +7 more
wiley +1 more source